Why MeadPierce?

Health Care and Life Science Organizations are forced to navigate complex laws, varying regulations and expansive enforcement capabilities, whilst being viewed through the lens of public and investor opinion.  A compounding factor relating to the complexity of the environment that these organizations navigate is the escalating risk of exposure relating to Qui Tam (e.g., whistleblower) matters.

To understand the Qui Tam risk to an organization, the recent activity and litigation in this risk area is paramount.  For example, in 2020:

• Relators (a.k.a. whistleblowers) filed 672 lawsuits, which represents the 5th highest number of cases in reported history 
• Qui tam relators filed, on average, almost 13 new cases per week
• Of these 672 qui tam cases filed, 68% were related to Health Care and Life Sciences Organizations 
• Over 80% of all recoveries—amounting to almost $1.9 billion—came from the Health Care and Life Sciences Organizations

The risk of a Qui Tam matter to health care and life science organizations is substantial, with significant expense and employee time being diverted from an organization's revenues to absorb the cost of the associated investigation (and/or subsequent litigation), the costs of a potential settlement and negative impact with investors.   MeadPierce focuses its practice on providing education, coaching and navigational expertise to organizations concentrating on understanding and managing potential Qui Tam risk and exposure.